Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of NNC0363-0845 in Healthy and T1D Subjects
NCT04569994Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0363-0845 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Sep 2020; status: completed.
02
Drugs
NNC0363-0845
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04569994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569994.